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Abstract 
 
Malaria remains one of the most prevalent and life-threatening diseases. It is caused by 
infection with parasites of the genus Plasmodium and transmitted to humans through 
female Anopheles mosquitoes. Several species of Plasmodium cause malaria in humans 
but P. falciparum is the most lethal specie. Malaria parasites have a complex life cycle and 
in order to eradicate the disease, every stages should be considered for treatment. Due to 
the appearance and spread of resistant parasites to current therapies, it is urgent to 
discover novel antimalarial drugs that are effective against both blood and liver stages of 
infection by malaria parasites and endowed with the ability to block the transmission of the 
disease to mosquito vectors. Currently, artemisinin-based combination therapies are used 
for uncomplicated malaria. The endoperoxide bond of artemisinin plays a key role in the 
fight against disease. As it only activated by a high concentration of iron (II) that is present 
in the digestive vacuole of the parasites infecting erythrocytes, where they degrade host 
hemoglobin. In contrast, basal Fe (II) concentration in mammalian cells is very low. This 
particularity ensures the high selectivity of endoperoxide drugs. The goal of this work was 
to prepare an activity-based probe (ABP) designed to identify potential molecular targets 
of 1,2,4,5-tetraoxane-cyanopyrimidine hybrid antimalarials. Several of these hybrids have 
shown to be active against the blood and liver stages of malaria parasites, and thus 
identification of the molecular targets associated to this dual-activity profile may become 
relevant in the discovery of new antimalarial drugs to be used in eradication campaigns. A 
hybrid ABP combining the 1,2,4,5-tetraoxane core and a cyanopyrimidine containing an 
alkyne handle for click chemistry was designed and synthesized. The tetraoxane 
contained an adamantyl moiety to confer stability to the endoperoxide motif. The synthesis 
of a negative ABP tetraoxane-pyrimidine nitrile probe was performed. Finally, in order to 
monitor the distribution and accumulation of this compound, we coupled the ABP with a 
fluorescent NBD-based azide reagent via click (CuAAC) chemistry to give the 
corresponding hybrid fluorescent probe in moderate yields.  
Keywords: malaria, tetraoxanes, cyanopyrimidine, activity-based probe
   
Resumo  
 
A malária é uma das doenças infeciosas mais frequente em todo o mundo que afeta 
maioritariamente as regiões subdesenvolvidas. Segundo a Organização Mundial de 
Saúde, em 2015 surgiram cerca de 212 milhões de novos casos de malária e estima-se 
que no mesmo ano tenham ocorrido cerca de 429 mil mortes causadas pela malária. No 
entanto, não é possível conhecer-se o número exato de casos de malária porque a maioria 
das regiões endémicas de malária não possuem os recursos de diagnóstico necessários 
e ainda devido ao facto dos sintomas da doença serem bastante semelhantes a outras 
doenças existentes nas mesmas regiões. 
Esta doença é causada por parasitas protozoários do género Plasmodium e sabe-se que 
existem pelo menos cinco espécies responsáveis pela infeção em humanos, o P. vivax, 
P. falciparum, P. malariae, P. ovale e P. knowlesi. Em conjunto com o P. vivax, o P. 
falciparum é também o responsável pela maioria de casos de malária. Apesar do P. 
falciparum ser a espécie responsável pela malária mais severa e por isso o responsável 
pela maioria das mortes, o P. vivax consegue gerar formas latentes, os hipnozoitos, que 
podem voltar à circulação levando à recorrência da doença. 
Sendo parasitas, os Plasmodium necessitam de dois hospedeiros para se multiplicarem 
e desenvolverem, um mosquito e um humano. A malária é geralmente transmitida através 
da picada de uma fémea infetada do mosquito Anopheles, sendo que a espécie mais 
eficiente é o Anopheles gambiae. Assim que o mosquito se alimenta do sangue humano 
liberta esporozoítos presentes nas glândulas salivares que migram pela corrente 
sanguínea e se depositam nas células hepáticas. O ciclo de vida do parasita é complexo 
passando por uma fase hepática onde o parasita se reproduz assexuadamente nos 
hepatócitos, seguindo-se uma fase sanguínea. A fase hepática é assintomática surgindo 
apenas sintomas na fase sanguínea. É nesta segunda fase que também se formam as 
formas sexuais do parasita capazes de infetar outro mosquito continuando assim o ciclo 
de vida do Plasmodium. 
Apesar dos diversos esforços, atualmente não existe nenhuma terapia eficaz no 
tratamento da malária. Esta ineficácia pode-se dever a diversos fatores como a biologia 
e ecologia complexa dos parasitas Plasmodium e dos vetores Anopheles e o 
aparecimento de estirpes de parasitas resistentes aos fármacos. O tratamento na fase 
hepática tem sido a maior preocupação já que nesta fase o numero de parasitas não é 
tão elevado como na fase sanguínea. O desenvolvimento de fármacos antimaláricos tem 
sido maioritariamente focado na fase sanguínea do parasita da malária, mas a fase 
hepática da infeção do Plasmodium é um passo obrigatório para a maturação e replicação 
do parasita sendo por isso um alvo importante para a erradicação da malária. Durante a 
fase sanguínea da malária, os parasitas transportam hemoglobina para o vacúolo 
digestivo onde usam a hemoglobina como uma fonte essencial de aminoácidos. Esta 
degradação conduz à formação de ferro heme. O ferro heme é tóxico para o parasita, mas 
este consegue polimerizá-lo convertendo-o em hemozoína, um material biocristalino 
inerte. 
Os primeiros compostos descobertos para o tratamento da malária foram as quinolinas. 
Após diversas alterações estruturais sintetizou-se um composto chamado cloroquina. A 
cloroquina tem sido utilizada no tratamento da malária desde os anos 60 e apesar das 
suas inúmeras vantagens como a eficácia, segurança e a possibilidade de administração 
a mulheres grávidas e crianças, o aparecimento de estirpes resistentes à cloroquina 
tornou necessária a procura de novos fármacos.  
A descoberta do mecanismo de ativação da artemisinina pelo ferro do grupo heme e da 
importância do núcleo endoperoxídico para a atividade antimalárica levou à descoberta 
dos tetraoxanos como potenciais fármacos para o tratamento da malária. Após serem 
ativados pelo ferro, os endoperóxidos dão origem a radicais centrados no carbono e a 
espécies reativas de oxigénio capazes de causar stress oxidativo no parasita. Este 
método de ativação permite que os endopéroxidos sejam seletivos para o parasita já que 
são necessários elevados níveis de ferro heme no vacúolo digestivo que, em condições 
normais, não se encontram nas células mamíferas. 
Atualmente, a artemisinina não é utilizada devido ao seu perfil farmacocinético fraco como 
o baixo tempo de semi-vida, a pobre solubilidade e a baixa biodisponibilidade tendo sido 
por isso sintetizados derivados semissintéticos. Estes derivados semissintéticos podem 
ser utilizados em terapias combinadas com outros agentes antimaláricos de longa ação 
permitindo a eliminação eficaz do parasita e evitando o aparecimento de casos de malária 
resistentes a esta terapia. No entanto, foram já documentados os primeiros casos de 
resistência à artemisinina. Um dos derivados semissintéticos da artemisinina, o arteméter, 
é atualmente utilizado em terapia combinada com a lumefantrina (Coartem©) para o 
tratamento da malária descomplicada em adultos e em crianças. 
Devido ao aumento das espécies resistentes aos fármacos antimaláricos, a síntese de 
compostos híbridos com um mecanismo de ação duplo tem se tornado uma abordagem 
bastante promissora. Desta forma, sintetizou-se um tetraoxano que após ativação com o 
ferro leva à formação de dois compostos, uma molécula radicalar e altamente reativa 
capaz de alquilar biomoléculas essenciais para a sobrevivência do parasita e aumentar o 
stress oxidativo e uma segunda molécula capaz de inibir enzimas como a falcipaína. A 
falcipaína é uma família de proteases de cisteína que se encontram no vacúolo digestivo 
e que desempenham um papel muito importante na hidrólise da hemoglobina. A inibição 
da falcipaína impede que o parasita consiga degradar a hemoglobina em aminoácidos 
conduzindo à sua morte. Diversos inibidores de proteases de cisteína têm sido 
sintetizados com bons resultados in vitro e in vivo com uma característica comum, um 
grupo eletrofílico capaz de reagir com o resíduo de cisteína. 
Recentemente, foi descoberto um novo grupo de tetraoxanos híbridos ativados pelo ferro, 
capazes de inibir a falcipaína dentro do vacúolo digestivo do parasita, os tetraoxanos 
compostos por pirimidinas e nitrilos. O ataque nucleofílico pelos nitrilos no sítio ativo das 
proteases de cisteína resulta na inibição reversível e covalente das enzimas. 
O objetivo deste trabalho foi preparar uma sonda baseada na atividade (activity-based 
probe, ABP), projetada para identificar potenciais alvos moleculares de 1,2,4,5-
tetraoxanos híbridos antimaláricos. Para a obtenção do composto pretendido recorreu-se 
a um processo de síntese bastante extenso realizado em duas fases separadas. Primeiro 
realizou-se a síntese do tetraoxano e do núcleo pirimidínico e no fim, fez-se o acoplamento 
entre os dois. Os rendimentos de todos os passos de síntese realizados foram moderados 
a bons tendo-se conseguido sintetizar o composto pretendido. 
De forma a monitorizar e observar a distribuição e acumulação do nosso composto dentro 
dos parasitas, decidiu-se acoplar a ABP a uma sonda fluorescente. Após a síntese da 
sonda, esta foi acoplada à ABP através de química click. Esta reação realizou-se por uma 
cicloadição catalisada por cobre entre a azida da sonda e o alcino do tetraoxano. O facto 
das azidas e dos alcinos serem inertes na maioria das condições biológicas e orgânicas 
permite que este acoplamento ocorra dentro do sistema vivo sem interferir com os 
processos bioquímicos naturais por reações bioortogonais. Apesar de ter ocorrido reação 
e de se ter sintetizado o composto pretendido, o rendimento deste acoplamento foi baixo 
tendo por isso a necessidade de ser otimizado. Neste projeto, pretendia-se ainda 
sintetizar um análogo do nosso tetraoxano inativo. A síntese deste análogo teve 
rendimentos moderados a altos mas não foi completa. 
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Chapter I 
 
 
  
Synthesis and evaluation of chemical probes to study the biology of liver stage malaria parasites  
I. State of the Art 
I.1 Malaria 
 
Malaria was once a prevalent disease in most of the world but after the World War II, the 
use of chloroquine successfully1 eliminated malaria from the United States of America 
(USA) and Canada, Europe and Russia.2 Unfortunately, because of the rapidly increase 
an spread of antimalarial drug resistance1,2, relaxation of control efforts, and insecticide 
resistance in the mosquito vectors, malaria resurged in tropical countries from the 1970s 
to the 1990s. More recently, the donor funding increased, the control was improved and 
the enthusiasm for elimination and eradication also increased, reducing malaria 
prevalence again.2 
Human infections could be caused by five species of genus Plasmodium, P. vivax, P. 
falciparum, P. malariae, P. ovale and P. knowlesi.1 4 P. falciparum is the species that 
causes most of the malaria deaths. P. vivax and P. falciparum are the species responsible 
the most of the cases of malaria.2,4 Plasmodium parasites are eukaryotic organisms that 
require two hosts, a mosquito vector and a human, to multiply and develop. Malaria 
transmission occurs when an infected female Anopheles mosquito feeds from human 
blood.2,5 
According with the World Health Organization (WHO), in 2015 there were 212 million new 
cases of malaria and it was estimated that there were 429 thousand malaria deaths, being 
children and pregnant women the most affected. Malaria disease is most prevalent in 
African countries (90%) followed by the South-East Asia countries (7%) and the Eastern 
Mediterranean countries (2%). Most of the malaria deaths occur in the African Region 
(92%) followed by the South-East Asia Region (6%) and the Eastern Mediterranean 
Region (2%). Despite this data, the incidence rates of malaria new cases fell by 21% and 
malaria mortality fell by 29% globally between 2010 and 2015. The malaria mortality rate 
among children under 5 years also fell by 35%.6 In pregnancy, malaria causes indirect 
mortality from abortion and intrauterine growth retardation, which increases infant 
mortality.2 
The real number of malaria cases is not precisely known because many of the malaria 
endemic countries lack appropriate diagnosis resources and there are rural settings where 
the clinical features of malaria are very similar to other diseases that may coexist in the 
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same geographical areas.2 Due to the wide-scale development of malaria control 
interventions, the number of malaria endemic countries reduced from 108 to 91 between 
2000 and 2016 as shown in figure I.1. 
Figure I.1  Countries endemic for malaria in 2000 and 2016 (adapted from 6) 
 
The continent most affected by malaria is Africa due to several factors such as hot and 
humid climate, lack of resources and poverty. It is also in Africa that the most efficient 
species of vector, Anopheles gambiae, is found and where the species P. falciparum 
predominates, leading to more severe malaria.2 
Together with tuberculosis and AIDS, malaria is one of the three most frequent infectious 
diseases in the world .1 Malaria is the most important protozoan disease 
of human beings and is transmitted by Anopheles mosquitoes.2 4 
 
I.2 Life Cycle of Plasmodium 
 
The parasite life-cycle begins (figure I.2) when a female Anopheles stings (A) a human 
and during a blood feeding injects saliva containing sporozoites that enter the host's 
bloodstream.2,7 Then, the sporozoites travel to the liver (B), housed in functional units 
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called hepatocytes and reproduce asexually for a few days.2 At this stage the disease is 
asymptomatic. After about a week, sporozoites mature into schizonts, which burst and 
release numerous identical daughter cells called merozoites to the red blood cells, 
initiating another asexual life cycle (C).2 To hide from the immune system of the host, 
merozoites invades erythrocytes where the parasite develops into a blood schizont.7,8 
 
Figure I.2  Life cycle of P. falciparum  in human body and in anopheline mosquito. (A) Infection by 
Anopheles; (B) Sporozoites invades hepatocytes and multiplies; (C)  Explosion of schizonts and release of 
merozoites; (D) Transmission to mosquito (adapted from 8) 
 
When there are around 100 million asexual parasites in circulation, the symptoms of the 
disease begin to appear. Some parasites develop in sexual forms, the gametocytes. When 
the host is again bitten by an anopheline mosquito (D) the gametocytes are captured by 
the mosquito and reproduce sexually forming an ookinete and then an oocyst in the 
mosquito's gut. Finally, the oocyst explodes and release sporozoites, which migrate to the 
salivary glands of the insect from where they will be released during the next blood feed. 
This cycle can take about one month.2 
In the cases of P. vivax and P. ovale, some sporozoites turn into hypnozoites, a form that 
can remain dormant in the liver cells, causing relapses months or even years after the 
initial infection.7,9 
Symptoms of malaria usually develop in about 10-15 days after the infection and the most 
common malaria symptoms are fever, headache, and chills that difficult the diagnosis4,10 
because these symptoms are also found in other diseases like flu and viral infections.  
Synthesis and evaluation of chemical probes to study the biology of liver stage malaria parasites  
When treatment is not initiated within the first 24 hours, the infection can progress to a 
more aggressive form called severe malaria, developing other symptoms such as anaemia 
and respiratory distress, or even cerebral malaria that often leads to death.10 
Traditionally, the diagnosis of malaria is made by microscopic examinations that allow 
identifying and quantifying the degree of infection, through the detection of the malaria 
 waste product, hemozoin.4 
 
I.3 Antimalarial Drugs 
 
Despite the many efforts already underway to control malaria, there are several factors 
that do not allow an effective therapy such as the complex biology and ecology of 
Plasmodium parasites and their anopheline vectors, drug-resistant strains of parasites, 
and the efficiency of immune evasion of the parasites during blood-stage replication.3 
The treatment of the disease in its asymptomatic phase, the liver phase, has been a major 
concern because, at this stage, the number of parasites is not as high as in the blood 
stage. Due to the distinct metabolism between the two phases, the antimalarial drugs that 
work in the blood phase are not effective in the liver phase and, despite the efforts made 
in the last decades for treatment in the liver phase, there is still no totally effective 
antimalarial drug at this stage.3 
 
I.3.1 Quinolines 
 
I.3.1.1 Quinine 
 
Quinolines are aromatic compounds with two fused hexagonal rings, wherein carbon in 
the first position is replaced by a nitrogen. The first quinoline compound used as an 
antimalarial drug was quinine, 1 (figure I.3).11 
Quinine is an alkaloid extracted from the bark of cinchona tree and was found in the 
seventeenth century. According to a legend, an Indian was lost in an Andean jungle and 
with a high fever and thirsty drank from a pool of stagnate water surrounding by cinchona 
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trees. Surprisingly, his fever soon decreased, and he shared this accidental discovery with 
fellow villagers, who thereafter used extracts from the cinchona bark to treat fever.12 
After several changes in obtaining and using the bark of the cinchona tree, in 1890s 
quinine began to be used for the treatment of malaria until the 1920s when a new drug 
appeared, chloroquine (CQ, 2, figure I.3). Due to the appearance of resistance to CQ, 
quinine is still used for the treatment of severe malaria in combination with other drugs.12 
Figure I.3 - Structure of quinoline compounds, quinine 1 and chloroquine 2. 
 
The mechanism of action of quinine is still unknown, but it is known that its schizonticidal 
action against parasites of intra-erythrocytic malaria is rapid and also has gametocyte 
activity for P. vivax and P. malariae. Its oral and parenteral absorption is very rapid 
reaching maximum concentration within 1-3 hours and 80% of the drug is rapidly 
eliminated by hepatic biotransformation and 20% is excreted unchanged by the kidney. 
The half-life of quinine is between 11-18 hours.12 15 
The first case of resistance to quinine was reported in 1910. Resistance to quinine is 
usually low grade, with the drug retaining some activity but having its action delayed or 
diminished.12 After the second world war, CQ and pyrimethamine replaced quinine and the 
development of high-level resistance has been very slow.11 
 
I.3.1.2 8-Aminoquinolines 
 
The discovery of antimalarial activity of methylene blue 3 (figure I.4) led to the first 
attempts of synthetic antimalarial drugs. It was in 1891 that the first synthetic drug began 
to be used when Paul Ehrlich and Paul Guttmann cured two malaria patients with 
methylene blue.7 
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Replacement of the basic methyl side chains with a methyl side chain improved the activity 
of the compounds, so in the 1920s, Bayer Laboratories, connected methyl side chain with 
different heterocyclic systems such as the quinoline system leading the first synthetic 
antimalarial plasmoquine, later called pamaquine 4 (figure I.4) in 1925.7,11 Pamaquine 
then began to be used in 1926 but was found to be very toxic, later synthesizing an 
analogue, primaquine (PQ 5, figure I.4) in 1952.7,11 
The mechanism of action of PQ is not yet clear but is known to be active in the liver stage 
of the parasite and against latent forms of Plasmodium (hypnozoites), especially in P. vivax 
infections. In addition, it can prevent the spread of the disease by preventing the 
transmission of gametocytes to naive mosquitoes.7,16 Currently PQ is still used to eradicate 
the hypnozoites of P. vivax and P. ovale.7,11,17 
 
Figure I.4  Structure of methylene blue 3, pamaquine 4, primaquine 5. 
 
I.3.1.3 4-Aminoquinolines 
 
Later, German scientists of IG Farben tried to associate the basic side chain of pamaquine 
to heterocyclic ring systems that leads to the synthesis of acridine 6 (figure I.5) and 
resochin. Initially it was thought that the resochin would be too toxic and therefore was not 
used but later, after its re-evaluation, this compound was found to be safe at therapeutic 
concentrations. This finding led to resochin being called chloroquine and initiating clinical 
trials in 1943. CQ 2 has been used in the treatment of malaria since the 1960s. 7,11 
 
Figure I.5  Structure of acridine 6. 
 
CQ is a dibasic compound (pka1 = 8.1, pka2 = 10.2) which in its unprotonated form is able 
to cross the erythrocyte membranes of the parasites that accumulate in the DV, once the 
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DV has a low pH (5.0  5.4).18 This accumulation depends on the pH difference between 
the external environment and the DV and requires metabolic energy to occur. The passage 
of CQ through the membranes also implies the existence of sodium and hydrogen 
exchangers. CQ binds to the sodium-binding site and, when during the glycolysis the 
generated protons are released to the external medium of the vacuole, CQ can penetrate 
the vacuole.11 
Iron is a required element for all living organisms and is the most abundant transition metal 
in the human body. Most of the iron present in the human body is in ferric form, Fe (III).19 
During the symptomatic phase of malaria, ferrous iron, Fe (II), is present in large quantities  
and can invade red blood cells.19 After invasion, Plasmodium parasites transport 
hemoglobin to the digestive vacuole (DV).11,19  
In DV, parasites use hemoglobin as source of essential aminoacids. Degradation of 
hemoglobin leads to a ferrous heme. This is a toxic byproduct called ferriprotoporphyrin IX 
(FPIX), but the parasite can convert it into an inert biocrystalline material containing heme 
oxidized Fe (III) called hemozoin by polymerizing the heme.7,11,19,20 In hemozoin crystals, 
heme is present as -hematin and the crystals are made of dimers of hematin molecules 
that are linked by hydrogen bounds forming a large structure with the ferric iron of each 
heme moiety chelated onto a carboxyl side chain of the adjacent moiety (figure I.6).11,20 
Although this form is less toxic, it is thought that the concentration of Fe (II) in the infected 
red blood cells is higher than the concentration present in healthy tissues and serum.19 
Mechanism of action is not yet fully understood but is thought that after CQ penetration in 
DV, CQ forms a complex with FPIX and thereby prevents its polymerization into hemozoin 
leading to parasites death.7,11 After treatment with CQ, swelling of the digestive vacuole of 
the parasite and accumulation of hemoglobin not ingested in endocytic vesicles is 
observed. These observations allowed us to conclude that CQ is only active in the blood 
stage of malaria during which degradation of hemoglobin in the parasite occurs, thereby 
interfering with its feeding process.11 
CQ presents a lot of advantages like its efficacy and safety and can be administered to 
children and pregnant women.21 Due to these advantages and the low cost of production, 
the use of CQ began to be abusive and combined with the high adaptability of Plasmodium 
parasites, the first cases of resistance began to appear. Today, more than 80% of wild 
isolates are resistant to CQ.7 The mechanism of resistance to chloroquine is also unknown, 
but in some resistant strains, CQ apparently undergoes a mutation and is removed from 
DV. In chloroquine-resistant strains high levels of glutathione are observed and therefore 
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it is thought that glutathione reductase may be another target of the FPIX -chloroquine 
complex.22 
 
 
Figure I.6  Chemical structures of heme, -hematin and hemozoin. (adapted from 23) 
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I.3.1.4 Quinolinemethanols 
 
Due to problems in Vietnam with CQ-resistant malaria in 1963, the Walter Reed Army 
Institute for Research (Washington, DC, USA) began large-scale screening for new 
potential antimalarial drugs. With this investigation, they found that 4-quinolinemethanols  
with analogue structures of quinine were the most promising group. In 1970, a new 
compound called mefloquine (MQ 7, figure I.7) was synthesized. MQ showed an even 
more potent activity than CQ and its great advantage was the efficacy against CQ resistant 
strains of malaria parasites.11 
Prophylactic use of mefloquine is prohibited for people who require unimpeded skills, such 
as air crew members, because mefloquine triggers some neuropsychiatric side effects 
such as insomnia, depression and panic attacks.7 
 
Figure I.7  Structures of 4-quinolinemethanols, mefloquine 7, halofantrine 8 and lumefantrine 9. 
 
In addition to the 4-quinolinemethanols found, the Walter Reed Army Institute for Research 
(Washington, DC, USA) found that replacing the quinoline of 4-quinolinemethanols with a 
different aromatic system led to the formation of aryl(amino)carbinols. Of this group of 
compounds, halofantrine 8 (figure I.7) was the most promising and was introduced into 
the treatment of CQ-resistant malaria but its use was banned because of the serious 
cardiotoxic problems it triggered.7,11 
Lumefantrine 9 (figure I.7) was developed in the 1970s by the Academy of Military 
Sciences in Beijing, China. Although lumefantrine exhibits less antimalarial activity than 
halofantrine, this drug has the advantage of not triggering cardiotoxicity problems of the 
halofantrine. Presently, lumefantrine is used in combination with endoperoxides drugs.7 
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I.3.2 Pyrimethamine/Sulfadoxine 
 
Pyrimethamine 10 (figure I.8) was discovered during the World War II and in 1950s was 
being used as a monotherapy against malaria parasites. A decade later, sulfadoxine 11 
(figure I.8) proved to be an effective, slow-acting blood schizontocide in clinical trials and 
the combination of pyrimethamine-sulfadoxine was later used as a treatment for falciparum 
and vivax malaria, including CQ-resistant strains.24,25 
 
Figure I.8  Structures of pyrimethamine 10 and sulfadoxine 11. 
 
Combination of these two drugs represent a major advantage when compared to 
monotherapy because pyrimethamine acts as dihydrofolate reductase inhibitor (DHFR 
inhibitors) while sulfadoxine acts as dihydropteroate synthase inhibitor (DHPS inhibitors).26 
These two enzymes are involved in the folate cascade to synthesize some nucleotides 
and aminoacids by malaria parasites and thus, inhibition of these two enzymes leads to 
synergism. DHFR enzyme converts dihydrofolate into tetrahydrofolate that is an essential 
cofactor in transfer reactions in the purine, pyrimidine, and amino acid biosynthetic 
pathways. DHPS is involved in the synthesis of folate, an essential substrate used in the 
folate cascade.24,26 
 
I.3.3 Falcipain, as a validated target  
 
Identification of the role played by cysteine proteases in the parasite life cycle has become 
essential for the discovery of new compounds capable of interacting with these 
enzymes.27,28 Among the proteases found in DV involved in the hydrolysis of hemoglobin 
the most influential in this process are falcipains.29 
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Falcipains (FP) are a family of papain-family cysteine proteases that includes four isoforms 
of falcipains, falcipain-1 (FP-1), falcipain-2 (FP-2), falcipain- - -3 (FP-
3).30 32 
FP-2 and FP-3 contribute equally to the digestion of hemoglobin in digestive vacuole33 and 
both enzymes are expressed during the erythrocyte stage of the parasite. FP-2 beginning 
in early trophozoites followed by expression of FP-3 in late trophozoites and schizonts.34 
Their inhibition results in inhibition of hemoglobin hydrolysis resulting in excess heme iron 
in the parasite that blocks parasite development.31 FP-2 also plays a crucial role in the 
erythrocyte rupture affecting the merozoites release.35 
Falcipains are dependent on a common catalytic triad constituted by cysteine, asparagine 
and histidine residues.36 Active site of cysteine proteases enzymes is constituted by four 
pockets S1, S1', S2 and S3. S1 is the least defined pocket which normally keeps the 
glutamine in the "oxyanion hole". Tryptophan is the most conserved residue in the S1' 
pocket and participate in hydrophobic interactions with substrates.37 S2 is the most well-
38 Most of residues of S2 
pocket are hydrophobic but sometimes a polar residue is present, like glutamic or aspartic 
acid. Finally, S3 pocket is a glycine rich region.37 Figure I.9 highlights the active site of 
FP-3  
 
Figure I.9  Representation of the falcipain- . 
(adapted from 37).  
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Several cysteine protease inhibitors have been synthesized with good results in vitro and 
in vivo with a common feature, an electrophilic warhead capable of reacting with the 
cysteine residue.33,38  
Alkyl and arylamines are well established inhibitors of cysteine proteases.31,39,40 Coterón 
and co-workers developed a large library of cysteine protease inhibitors based on a 
general structure (figure I.10) with an electrophilic moiety for interaction with the cysteine 
residue of the enzyme and one or two series of substituents responsible for interactions 
with the different pockets of the protease.31 FP-2 has been shown to have preference for 
substrates with a hydrophobic residue, particularly leucine, at position P2.33,38 Leucine-like 
isobutyl moiety was the most potent derivative against FP enzymes.31 Compounds with 5-
bromopyrimidine and 5-chloropyrimidine scaffolds in P1 also proved to be the most 
promising, showing a clear advantage in terms of enzymatic activity over other nitriles. 
 
 
Figure I.10  General structure of 2-pyrimidinecarbonitrile derivatives showing positions P1, P2 and P3. 
 
I.3.4 Endoperoxides  
 
An endoperoxide is a heterocyclic compound containing a peroxide (-O-O-) residue in the 
ring. It is accepted that this kind of compounds are activated by the iron or heme present 
inside the parasite by scission of the peroxidic bond. When this activation occurs, it leads 
to the formation of oxygen radicals that undergo a rearrangement resulting in carbon-
centered radicals that can interfere with several targets. These are extremely reactive 
species and may alkylate the parasite biomolecules essential for his survival and 
simultaneously contributes to increase oxidative stress that makes very difficult for 
parasites to survive.7 
In normal conditions, the concentration of free Fe (II) in mammalian cells is lower than 
inside the DV of Plasmodium parasites. Thanks to this difference, endoperoxides are 
essentially activated in the parasite providing a high degree of selectivity and safety of this 
group of drugs.41,42 
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Many parasitic proteins, such as falcipain (FP) proteases, and the heme itself responsible 
for activation of the endoperoxides can be alkylated by the formed radicals which may 
interfere with the elimination of the heme leading to the death of the parasite.20 Lipophilic  
heme adducts can accumulate in neutral lipid bodies around the DV membrane and 
increase oxidative stress resulting in the oxidative degradation of phospholipids.20,43 
 
I.3.4.1 Artemisinin 
 
During the Vietnam War, Chinese government formed a research group to find drugs to 
defend the army against malaria infections. Due to its use to treat fevers, chills and 
convulsions, Artemisia annua was chosen to be investigated. Its active ingredient, 
artemisinin (ART 12, figure I.11) was isolated for the first time in 1971.7,44 
 
 
Figure I.11  Structures of artemisinin 12 and its analogues, dihydroartemisinin 13, artemether 14, arteether 
15 and artesunate 16. 
 
ART is a sesquiterpene lactone with a peroxidic bond fundamental for antimalarial activity  
and has been used in China for treatment of malaria since 1972.7,20,45 It is an effective 
antimalarial drug in low nanomolar range against multiresistant strains of P. falciparum 
and is only active on blood stage.7,20,44 There are some ART analogues with activity against 
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other types of parasites of the genus Trypanosoma, Leishmania and Toxoplasma46 and 
also with antitumor20 and antifungal activity46. 
Activation of ART by iron (II) can give rise to different types of radicals capable of alkylating 
the heme group and proteins resulting in the death of Plasmodium. ART activation leads 
to generation of carbon-centered free radicals or reactive oxygen species (ROS).45 When 
Fe (II) binds to oxygen 1 of artemisinin (Route 1, scheme I.1), oxygen radicals are formed. 
Subsequently occurs an electron transfer inducing reductive scission of the C3-C4 bond 
giving rise to carbon radicals. On the other hand, when the iron binds to oxygen 2 (Route 
2, scheme I.1) oxygen radicals are also formed and this process is then followed by an 
intramolecular 1,5-H migration leading to carbon radicals.20,45,47 Selectivity of ART results 
from the fact that ferrous heme is present in high concentration inside the parasite.48 
  
Scheme I.1  Activation mechanism of ART by Fe (II). 
 
Although many authors believe that the activation of ART occurs with heme iron there is 
also evidence that this activation may also occur with non-heme iron. Stocks and co-
workers demonstrated that the presence of desferrioxamine (DFO) antagonize the 
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antimalarial activity of artemisinin in vitro. DFO is a chelating agent selective for Fe (III). 
This demonstrate that activation of ART is also dependent on non-heme iron.49,50 
Several potential targets have already been proposed for the ART but its mechanism of 
action is still unclear. Meshnick et al. was the first to identify heme-drug adducts proving 
that ART is capable to alkylating heme. As result of this alkylation, heme polymerization 
and hemozoin formation are interrupt leading to the parasite death. Beyond heme 
alkylation, it was shown that ART is also capable of inhibit falcipains, a papain family 
cysteine protease involved in hemoglobin degradation.20,51 
Currently ART is not used due to its poor pharmacokinetic profile as the short plasma half-
life, limited bioavailability and poor solubility in water and oil, so the development of 
semisynthetic derivatives (figure I.11) such as dihydroartemisinin (DHA 13), artemether 
14, arteether 15 and artesunate 16 was a breakthrough in malaria treatment.44 
Although artemisinin derivatives have low half-lives, they are currently used in artemisinin 
combination therapies (ACT). In this strategy, ART and its semi-synthetic derivatives are 
combined with other long-acting antimalarial agents. This leads to effective parasite 
clearance and avoids the risk of resistance development.46 WHO recommended the use 
of ACTs as first-line treatment of uncomplicated falciparum malaria in all malaria-endemic 
areas. The first signs of artemisinin resistance appeared on Thai-Cambodian border were 
the efficacy of ACT and artesunate monotherapy have decreased.52 54 Currently the only 
artemisinin-based combination therapy available combines artemether with lumefantrine 
for treating uncomplicated falciparum malaria in adults and children (Coartem©).7,45 
 
I.3.4.2 Tetraoxanes 
As an alternative to artemisinin, several fully synthetic peroxidic analogues such as 1,2,4-
trioxanes 17, 1,2,4-trioxolanes 18 and 1,2,4,5-tetraoxanes 19 have been developed 
(figure I.12). These derivatives, are also activated by Fe2+ and exert their mode of action 
through the formation of radical species.7 
Tetraoxanes are rapidly and effectively activated by heme iron inside the parasite by 
scission of the peroxidic bond generating carbon-centered radicals that lead to the 
formation of heme adducts and ketone byproducts.29,55 
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Figure I.12  General structures 1,2,4-trioxanes 17, 1,2,4-trioxolanes 18 and 1,2,4,5-tetraoxanes 19. 
 
In 1992, Vennerstrom and co-workers also synthesized molecules with two endoperoxide 
groups, dispiro1,2,4,5-tetraoxanes 20a-d (figure I.13). These compounds proved to be 
equally effective as artemisinin and could be synthesized in only one step from cheap 
materials.56 58 The efficacy and low production costs of tetraoxanes have made this type 
of compounds very promising in the treatment of malaria.56,59 Like ART, despite its 
effectiveness, first-generation tetraoxane derivatives showed a poor pharmacokinetic 
profile due to its low lipophilicity and low bioavailability.60  
Figure I.13  Compounds synthesized by Vennerstrom. 
 
I.4 Hybrid drugs based on tetraoxanes 
 
Due to the increase of resistant strains to most of the available antimalarial drugs, 
combination of two  or more drugs has become a very interesting approach.61,62 Hybrid 
drugs consist of the binding of two pharmacophores with different mechanisms of action 
covalently linked to each other.62,63 
Compared to combination therapy, hybrids compounds only have a single active 
pharmaceutical ingredient and therefore the associated costs of production  and 
purification are lower.64 As the administration is done with only one tablet or one injection, 
patients acceptance of this therapy is also greater. In addition to increasing efficacy and 
consequently decreasing the risk of treatment failure, the hybrid drugs can be more 
effective due to the synergism than drug combination allowing the use of smaller doses 
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and hence a greater margin of safety and a low toxicity. The hybrid combination of two 
drugs is limited to a fixed ratio of 1:1 in which the pharmacophores share the same 
pharmacokinetic and pharmacodynamic profile.62 
This approach also has some limitations. When the volume of the hybrid reduces the 
penetration of the drug into the parasite cell the efficacy of treatment may decrease.62 
Another disadvantage of hybrid drugs is the difficulty of adjust the ratio of activities at 
different targets.61 
The molecular properties of the hybrid compounds should be studied in silico for drug-
likeness assessment based on Lipinski's rule of five. It states that poor absorption or 
permeability of a compound is more likely when there are >5 hydrogen-bond donors, the 
molecular mass is >500, calculated log P is >5, and the sum of nitrogen and oxygen atoms 
in a molecular is greater than 10.65 
 
I.4.1 Tetraoxane-pyrimidine nitrile hybrids 
A class of covalent inhibitors that have been used are nitrile-based inhibitors.66 
Nucleophilic attack of nitriles at the active site by cysteine protease results in the formation 
of a reversible and covalent thiomidate intermediate leading to its inhibition.27,28,66 In order 
to inhibit the protease, an inhibitor must possess an electrophilic fraction for the cysteine 
residue in the active site of the enzyme and within hydrogen bonding distance to a histidine 
residue (His).31,66 Scheme I.2 shows the reaction mechanism of cysteine protease with 
nitrile inhibitors. 
 
Scheme I.2  Reaction mechanism of cysteine protease with nitrile inhibitors. 
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O'Neill and co-workers have shown that tetraoxane-pyrimidine nitrile hybrids 21 (figure 
I.14) are activated by Fe (II) and are able to inhibit FP within the DV of the parasite. They 
studied their activity against blood and liver stages of malaria infection in murine models. 
These new compounds showed to have higher FP-2 inhibitory activity with IC50 values 
between 3.4 and 978 nM (table I.1).28 
 
Figure I.14  Tetraoxane-pyrimidine nitrile hybrids 21. 
 
Vennerstrom and co-workers showed that 1,2,4-trioxolanes substituted with an 
adamantane ring are not only chemically stable but active against P. falciparum in the low 
nanomolar range.7,67,68 Recently, -workers concluded that adamantyl group 
is responsible for increasing the lipophilicity and stability of the endoperoxide motif and its 
presence seems to be essential to increase the activity of tetraoxane-based chemical 
hybrids.28,29,69,70 
 
Table I.1  Falcipain-2 inhibition and antiplasmodial activity of tetraoxane-pyrimidine nitrile hybrids 21. 
(adapted from 28) 
    IC50[nM] 
Compound X R1 R2 FP-2 
21a CO _CH2CH(CH3)2 5_Br 16.4±4.2 
21b CH2CO _CH2CH(CH3)2 5_Br 95.1±0.4 
21c CO _CH2CH(CH2)4 5_Br 112±9 
21d CO _CH(CH2)5 5_Br 25.3±7.1 
21e CO _CH2CH(CH3)2 5_Cl 3.4±0.6 
21f CO _CH2CH(CH3)2 5_H 909±93 
21g CO _CH2CH(CH3)2 6_Cl 978±205 
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I.5 Activity-based probes and click reaction 
 
Activity-based proteomics has been developed to characterize protein activity and directly 
monitor the functional regulation of enzymes in complex proteomes. This method utilizes 
small molecule activity based probes (APBs) which covalently modify the enzyme active 
site and enable detection and affinity purification of a target enzyme population.71 ABPs 
can be viewed as chemical antibodies to report on the expression of a protein, but at the 
same time as probes to detect the target active enzymes in a living system.72 
 
Figure I.15  1,2,4-trioxolanes-ABPPs and artemisinin-ABPPs compounds. 
 
In spite of the recent increase in endoperoxide antimalarials under development, it remains 
unclear if all these chemotypes share a common mechanism of action.  Activity-based 
et al. synthesized 
activity-based protein profiling probes (ABPPs) based on a 1,2,4-trioxolane antimalarial 
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core (22 and 23, figure I.15) and artemisinin core (24 and 25, figure I.15) in order to 
characterize their malaria parasite protein alkylation fingerprint. They verified that the 
active probes containing azide/alkyne functionality retained potent antimalarial activity as 
determined by their IC50 in vitro against P. falciparum parasites while the non-peroxidic 
negative control probes (26 to 29, figure I.15) had not appreciable activity in these assays, 
confirming the essentiality of the endoperoxide-bridge for drug activity.73,74 
The click chemistry reactions allows the use of small size of the functional groups like 
alkyne groups to provide fluorescence in situ.75 Since Sharpless and co-workers 
introduced the so called click chemistry concept, this tool has become very powerful in 
biomedical research. These reactions should be fast, simples, stereospecific and give 
products in very high yields with formation of inoffensive byproducts that can be removed 
by nonchromatographic methods. Huisgen 1,3-dipolar cycloaddition like cooper-catalyzed 
azide-alkyne cycloaddition (CuAAC) (scheme I.3) is the most widely used.76,77 In this 
reaction, azides and alkynes react with one another to form a triazole. 
often does not hinder the permeability of an ABP, but isolation depends on efficiency of 
the click reaction and subsequent isolation steps.78 
Alkyne groups were used as surrogate groups for later addition of reporter tags by click 
chemistry to reduce adverse interactions between bulky tags and the target enzymes.79 
Azides and alkynes are inert to most biological and organic conditions, molecular oxygen, 
water, and the majority of common reaction conditions in organic synthesis.76 This property 
allows highly bioorthogonal fluorescent labeling in living and complex samples.75 
 
Scheme I.3  Catalytic cycle of CuAAC. (adapted from 80)  
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I.7 Goals of the project 
 
As mentioned earlier, the parasites use hemoglobin as a source for the synthesis of 
essential amino acids. The high selectivity of endoperoxide drugs is one of its most 
important characteristics since they are only activated by a high concentration of iron (II) 
that is not present in mammalian cells. 
The main goal of this project is to synthesize new tetraoxane-pyrimidine nitrile hybrids 
ABPs 30 (scheme I.4) with an adamantyl group as part of a larger project to identify the 
molecular targets of antimalarial hybrid drugs. The resulting tetraoxane-pyrimidine nitrile 
hybrid 30 should be activated by iron (II) and release a potent falcipain inhibitor byproduct 
inside the parasites (scheme I.4). 
 
 
Scheme I.4  Structure of tetraoxane-pyrimidine nitrile hybrid 30 and release of potent FP-2 inhibitor. 
 
Moreira lab recently identified a low molecular weight pyrimidine nitrile that inhibits both 
liver and blood stages. This validated drug-like hit is a potent inhibitor of falcipain-2, a 
cysteine protease involved in host heme degradation in the blood stage but absent in the 
liver stage of the parasite. 
This work should be accompanied by an inactive close analog of our 
tetraoxane-pyrimidine nitrile hybrid 30. We decide to use the dioxane-pyrimidine nitrile 
hybrid 31 (figure I.16) as a negative control. 
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Figure I.16  Structure  31. 
 
To monitor and observe our tetraoxane-pyrimidine nitrile hybrid 30 and compound 31 
inside the parasites, we decided to couple both compounds to a fluorescent probe.  
The fluorescent tag selected for this assay was nitrobenzoxadiazole (NBD) once it was 
previously used in Plasmodium to visualize accumulation of endoperoxides and could be 
visualized using confocal microscopy. This will lead us to chemical probes 32 and 33 
(figure I.17). 
 
 
Figure I.17  Structure of chemical probes 32 and 33. 
 
  
 
 
 
 
Chapter II 
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II. Methods, results and discussion 
 
All the NMR results used for the characterization of synthesized compounds are 
presented in Chapter VI. 
 
II.1 Tetraoxane-pyrimidine nitrile hybrid 
 
We used a convergent synthetic approach to prepare the tetraoxane-pyrimidine nitrile 
hybrid ABP 30. Tetraoxane and pyrimidine nitrile intermediates were synthesized 
separately and coupled in the final step. Scheme II.1 illustrates the retrosynthetic analysis 
of tetraoxane-pyrimidine nitrile hybrid 30. 
 
Scheme II.1  Retrosynthetic analysis pathway for the synthesis of hybrid 30.  
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Synthesis of intermediate pyrimidine nitrile 37 (scheme II.2) started with the alkylation of 
Boc-hydrazine 34 by a second-order nucleophilic substitution (SN2) reaction with propargyl 
p-toluenesulfonate as the electrophile. 
Scheme II.2  Synthesis of intermediate pyrimidine nitrile 37. Reagents and conditions: (i) propargyl p-
toluenesulfonate, DIPEA, dry DCM, 0ºC, 4h, N2; (ii) 5-bromo-2,4-dichloro pyrimidine, DIPEA, dry EtOH, 
reflux, ov, N2; (iii) p-toluenesulfonic acid, ACN, rt, ov. 
 
To avoid dialkylation of Boc-hydrazine 34 to a minimum, the temperature was maintained 
at 0ºC. The product 35 was identified by 1H-NMR (figure VI.1). The triplet at 2.25 ppm 
integrating to one hydrogen and the dublet at 3.63 ppm integrating to two hydrogens 
correspond to alkyne hydrogen and to CH2 adjacent to the sp carbon of the alkyne, 
respectively.  
Compound 36 was obtained from a nucleophilic aromatic substitution between hydrazine 
35 and 5-bromo-2,4-dichloro pyrimidine. In basic conditions, this substitution occurs 
preferentially in position 4 of the pyrimidine.31 The appearance of a singlet integrating to 
one hydrogen at 8.35 ppm in 1H-NMR spectrum (figure VI.2) corresponds to the aromatic 
proton and proved the product formation. In IR spectrum (figure VI.7) was observed a 
broad band at 3300 cm-1 which corresponds to the primary amine and a band at 1726 cm-
1 which corresponds to the carbonyl of carbamate.  
Deprotection of compound 35 with p-toluenesulfonic acid and subsequent neutralization 
with sodium carbonate 1M led to the synthesis of compound 37. The formation of this 
compound was proved by the disappearance of the singlet at 1.49 ppm correspondent to 
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the Boc group and the appearance of a broad singlet integrating for two hydrogens  
correspondent to NH2 at in 1H-NMR spectrum (figure VI.8). 
In IR spectrum of compound 37 (figure VI.9) was observed the disappearance of the band 
at 1726 cm-1 which means that Boc group was removed and the peaks 3308 and 3273 cm-
1 corresponds to the primary amine. 
Synthesis of tetraoxane 42 was made four steps (scheme II.3). Tetraoxane ester 40 was 
prepared from 38, by an acid-catalyzed cyclocondensation procedure described by  
et al. (scheme II.4).59 
Scheme II.3  Synthesis of intermediate tetraoxane 42. Reagents and conditions: (i) HCOOH, H2O2 50%, 
dry ACN, rt, 1h, N2; (ii) 2-adamantanone, Re2O7, dry DCM, rt, 3h, N2; (iii) MeOH, NaOH, H2O, reflux, 1h; (iv) 
SOCl2, DMF, reflux, 6h. 
 
Reaction of ethyl-4-oxocyclohexane-1-carboxylate 38 with hydrogen peroxide (H2O2) and 
formic acid (HCOOH) leads to the corresponding gem-dihydroperoxide 39. Tetraoxane 
ester 40 was achieved by cyclization of the gem-dihydroperoxide 39 with 2-adamantanone 
using rhenium (VII) oxide (Re2O7) catalyst. Re2O7 in DCM offers a mild and highly efficient 
catalysis for the condensation of carbonyl groups with 1,1-dihydroperoxides to form 
1,2,4,5-tetraoxanes.81 
In 1H-NMR spectrum (figure VI.10) was verified that CH2 and CH3 of ester group appeared 
as a quartet at 4.13 ppm integrating to two hydrogens and a triplet 1.24 ppm integrating to 
three hydrogens, respectively. The signal at 174.60 ppm in 13C-NMR spectrum (figure 
VI.12) confirms the presence of the carbonyl carbon of ester function and the tetraoxane 
core was identified through two characteristic signals for C1 and C2 at 110.5 ppm and 
107.2 ppm, respectively. 
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Scheme II.4  Proposed reaction mechanism for the synthesis of tetraoxane ester 40. 
 
Tetraoxane ester 40 was subsequently hydrolyzed to tetraoxane acid 41 using sodium 
hydroxide (NaOH). In 1H-NMR spectrum (figure VI.16) was observed the disappearance 
of the triplet at 1.24 ppm and the quartet at 4.13 ppm of the CH3 and CH2, respectively. 
Reaction of the tetraoxane acid 41 with thionyl chloride and catalytic dimethylformamide 
(DMF) led to the formation of the final tetraoxane intermediate 42 (Scheme II.5). DMF 
reacts with thionyl chloride giving the iminium intermediate that subsequently reacts with 
the carboxylic acid resulting in the acid chloride formation. 
Scheme II.5  Mechanism of reaction of an acid with thionyl chloride catalyzed by dimethylformamide.  
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Synthesis of the final tetraoxane-pyrimidine nitrile hybrid 30 followed the mechanism 
represented in scheme II.6. 
 
Scheme II.6  Synthesis of tetraoxane-pyrimidine nitrile hybrid 30. Reagents and conditions: (i) DIPEA, dry 
THF, rt, ov, N2; (ii) DABCO, KCN, DMSO/H2O, rt, 4h30. 
 
First, the coupling of deprotected pyrimidine 37 and tetraoxane 42 was performed in basic 
conditions with DIPEA and under nitrogen atmosphere. This step led to the formation of 
tetraoxane-pyrimidine hybrid 37 in moderate yields. In 1H-NMR spectrum (figure VI.18) 
was observed two moieties in 1:1 ratio and the conversion of the primary amine at 4.30 
ppm to a secondary amide at 7.79 ppm. 
Finally, tetraoxane-pyrimidine hybrid 43 was treated with potassium cyanide in basic 
conditions to give the final tetraoxane-pyrimidine nitrile hybrid 30. The conversion of 
compound 43 in compound 30 is observed by the displacement of the pyrimidine hydrogen 
from 8.33 ppm to 8.53 ppm in 1H-NMR spectrum (figure VI.24) and the appearance of the 
peak of CN at 115.14 ppm in the 13C NMR (figure VI.26). 
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II.2 Tetraoxane-pyrimidine nitrile probe 
 
To synthesize the tetraoxane-pyrimidine nitrile probe 32 first was prepared the 
fluorescent tag 46 (Scheme II.7). 
 
Scheme II.7  Synthesis of fluorescent tag 46. Reagents and conditions: (i) NaN3, KI, THF:H2O (3:1), reflux, 
ov; (ii) NBD-Cl, NaHCO3, MeOH, reflux, 3h. 
 
First, sodium azide was added to the halogenated carbon chain 44. The resulting mixture 
was added to 7-chloro-4-nitrobenzoxadiazole (NBD-Cl) in basic conditions to afford 
compound 46. 1H-NMR spectrum (figure VI.30) was consistent with the structure. 
The final tetraoxane-pyrimidine nitrile probe 32 was prepared from tetraoxane-pyrimidine 
nitrile hybrid 30 and the fluorescent tag 46 (scheme II.8) by a cooper-catalyzed alkyne-
azide 1,3-dipolar cycloaddition described by Ruivo et al.82  
Scheme II.8  Synthesis of tetraoxane-pyrimidine nitrile probe 32. Reagents and conditions: (i) CuSO4, 
sodium ascorbate, DMF, TEA, rt, 25h. 
 
The click reaction was proceeded at room temperature in basic conditions with 
triethylamine. Sodium ascorbate was used as a reducing agent to prevent the oxidation of 
the copper sulphate and to produce copper (I) in situ.83,84 The product was obtain with low 
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yield. The formation of cyclic 1,4-triazole was confirmed by 1H-NMR due to the presence 
of a singlet at 9.13 ppm and the absence of propargyl CH signal (figure II.1). 
 
 
Figure II.1 - 1H-NMR spectrum (CDCl3) of tetraoxane-pyrimidine nitrile probe 32. 
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II.3 Dioxane-pyrimidine nitrile hybrid 
 
As tetraoxane-pyrimidine nitrile hybrid 30, synthesis of dioxane-pyrimidine nitrile hybrid 33 
was made in two separately steps. Intermediates, dioxane and pyrimidine nitrile, were 
separately synthesized and in the end, were coupled. Scheme II.9 illustrates the 
retrosynthetic analysis of dioxane-pyrimidine nitrile hybrid 31. 
 
 
Scheme II.9  Retrosynthetic analysis pathway for the synthesis of hybrid 31. 
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In order to obtain the dioxane 51 with the carboxylic acid group, we started with 2-
adamantanone 47, according to Scheme II.10. 
 
Scheme II.10  Synthesis of dioxane 51. Reagents and conditions: (i) KHMDS.hexane, CH3OCH2PPh3Cl, 
dry THF, 0ºC, 4h, N2; (ii) HCl, ACN, rt, ov; (iii) CH2O, NaOH, THF:MeOH (2:3), rt, 18h; (iv) method A: 38, p-
TsOH, dry toluene, Dean-Stark conditions, 18h; method B: 38, ZrCl4, (EtO)3CH, dry DCM, rt, 45 min, N2; (v) 
NaOH, MeOH, H2O, reflux, 2h. 
 
Synthesis of dioxane 51 started with 2-adamantanone 47 to obtain aldehyde 48. This 
reaction was made by three different methods using three different bases and a 
phosphonium salt in a Wittig-Horner reaction followed by hydrolysis in acidic conditions 
(scheme II.11). In method A was used potassium bis(trimethylsilyl)amide (KHMDS)85, in 
method B was used n-butyllithium (n-BuLi)86,87 and in method C was used sodium hydride 
(NaH) as base. 
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Scheme II.11  Synthesis mechanism of aldehyde 48. 
 
Aldehyde 48 was not obtained using method B and method C but method A allowed the 
synthesis of aldehyde with moderate yields. 1H-NMR spectrum (figure VI.37) showed the 
characteristic signal of the aldehyde group at 9.73 ppm and is consistent with the 
literature.85 The multiplet at 2.00-1.58 ppm integrates to fourteen protons instead of twelve 
probably because of the presence of water in chloroform. 
Diol 49 was prepared according to Cannizzaro (scheme II.12).88,89 Treatment of the 
aldehyde 48 with formaldehyde in basic conditions leads to diol 49. First, the -hydrogen 
of the aldehyde reacts with formaldehyde by an aldol condensation -
hydroxyaldehyde. At the same time, a second molecule of formaldehyde reacts with an 
hydroxide ion producing a highly unstable dianion. The dianion formed transfers a hydride 
-hydroxyaldehyde forming the final diol 49 in moderate yields. 
 
Scheme II.12  Synthesis mechanism of diol 49. 
 
Synthesis and evaluation of chemical probes to study the biology of liver stage malaria parasites  
In 1H-NMR spectrum (figure VI.38) it was observed the disappearance of the signal of the 
aldehyde proton and the appearance of a singlet integrating to four hydrogens at 3.94 ppm 
referent to two dimethanol groups (CH2OH) of compound 49. 
Synthesis of dioxane ester 50 was tried by two different methods. In method A, reaction of 
ethyl-4-oxocyclohexane-1-carboxylate 38 with the diol 49 using Dean-Stark conditions 
was not successful and the product was not obtained. Method B was based in a reaction 
described by Firouzabadi et al.90 In this method the acetalization between of ethyl-4-
oxocyclohexane-1-carboxylate and the diol 49 was made using zirconium tetrachloride 
(ZrCl4) as catalyst. Method B afforded diol 50 in good yields. 
In 1H-NMR spectrum of compound 50 (figure VI.39) was verified that the signals of the 
CH2 and CH3 of ester function appeared as a quartet at 4.11 ppm integrating to two 
hydrogens and a triplet at 1.23 ppm integrating to three hydrogens, respectively. The 
signal at 175.34 ppm in 13C-NMR spectrum (figure VI.41) confirms the presence of the 
carbonyl carbon of ester function. 
Dioxane ester 50 was subsequently hydrolyzed in basic conditions to afforded dioxane 
acid 51. 1H-NMR spectrum (figure VI.45) was observed the disappearance of the triplet at 
1,23 ppm and the quadruplet at 4.11 ppm correspondents to CH3 and CH2, respectively. 
For the preparation dioxane-pyrimidine nitrile hybrid 52 (scheme II.13) we used O-
(Benzotriazol-1-yl)- -tetramethyluronium tetrafluoroborate (TBTU) at 0ºC to avoid 
a concentrated acid environment or high temperatures that could degrade the acetal. After 
the amide coupling reaction, the dioxane-pyrimidine nitrile hybrid 52 was characterized by 
1H-NMR and the product was not synthesized. 
 
 
Scheme II.13  Synthesis of dioxane-pyrimidine nitrile hybrid 52. Reagents and conditions: (i) TBTU, TEA, 
dry DCM, 0ºC, 1h, N2; (ii) 37, dry DCM, rt, ov, N2. 
  
 
 
 
 
 
 
Chapter III 
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III. Concluding remarks and future 
perspectives 
 
 
The emergence of drug-resistant pathogens is a major threat to human health, and P. 
falciparum exhibit its high propensity to develop resistance to every drug that has been 
deployed against it on a large scale. 
In chapter I, we revealed the opportunity to develop an improved delivery system based 
on endoperoxide to be used as a carrier of other drugs for malaria parasites. The 
pharmacological potential of tetraoxanes has boosted the strategies for the synthesis of 
new derivatives in order to expand the libraries of new compounds for studies of 
pharmacological activity and to allow the identification of new drug candidates. 
In order to develop a more drug-like compound, in this project we successfully designed 
and synthesized in moderate to good yields a new tetraoxane-pyrimidine chemical hybrid 
that can act by two distinct mechanisms of action, an essential feature to prevent selection 
of drug resistance. This compound is based in non-peptidic FP inhibitors that should be 
more viable for oral administration, moreover the fact they react reversibly with 
nucleophiles should prevent undesired toxicity. 
We also successfully developed a new hybrid ABP coupled to a fluorescent tag to be used 
in cellular localization assays. Studying the accumulation of that compound in Plasmodium 
parasites should provide information about the delivery process of FP inhibitors by 
tetraoxane systems. This compound should allow us to identify the molecular targets and 
to understand the mechanism of action in the blood and liver stages. 
Further work is needed to complete the synthesis of the negative ABP tetraoxane-
pyrimidine nitrile probe. Furthermore, these compounds should be evaluated for their 
metabolic stability and in vitro and in vivo efficacy. 
 
   
  
 
 
 
 
Chapter IV
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IV. Synthesis 
 
 
IV.1 Equipment 
 
NMR spectra (1D and 2D) were recorded on a Brucker 300 Ultra Shield. The chemical 
J) are expressed in Hz. 
Multiplicities are given as: s (singlet), d (duplet), t (triplet), q (quartet), quint (quintuplet) 
and m (multiplet). 
Infrared (IR) spectra were performed on a Nicolet Impact 400 FTIR spectrophotometer 
using thin films between NaCl tablets and only the most significant absorption bands are 
reported. 
Melting points were determined using a Kofler Bock Monoscop M. Camera and are 
uncorrected. 
Mass analysis were determined using a Micromass Quattro Micro API spectrometer, 
equipped with Watters 2695 HPLC Module and Waters 2996 Photodiode Array Detector. 
 
IV.2 Reagents 
 
Reagent grade chemicals were purchased from Alfa Aesar, Sigma-Aldrich or Merck.  
 
IV.3 Solvents 
 
Analytical grade solvents were used. Dichloromethane was dried from calcium chloride, 
acetonitrile from phosphorous pentoxide, ethanol from calcium hydride and distilled at 
atmospheric pressure. Tetrahydrofuran and diethyl ether were dried from sodium-
benzophenone system. Toluene was dried with sodium metal. All the solvents used in 
purification were distilled under reduced pressure. 
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Deutered chloroform used for NMR analysis was purchased from Merck with a degree of 
purity higher than 95%. 
 
IV.4 Chromatography 
 
Thin layer chromatography was performed on pre-coated silica gel 60 F254 (Merck) and 
visualized using a CAMAG UV cam at UV wavelength, iodine and ninhydrin, potassium 
permanganate, p-anisaldehyde and dinitrophenylhydrazine dip. 
Flash chromatography was performed with silica gel 60 M, 0.400-0.063 mm (Merck). 
Preparative thin-layer chromatography was performed with silica gel 60 GF254, 0.040-0.063 
mm (Merck). 
 
IV.5 Synthesis of tetraoxane-pyrimidine nitrile hybrid
 
IV.5.1 Synthesis of tert-butyl 2-(prop-2-yn-1-yl)hydrazine 
carboxylate (35) 
 
A solution of tert-butylcarbazate (2 mmol, 264 mg) and propargyl p-
toluenesulfonate (2 mmol, 420 mg, 346 µL) in dry dichloromethane (5 
mL) was stirred for 1h at 0ºC, under nitrogen atmosphere. Then, was 
added diisopropylethylamine (4 mmol, 517 mg, 697 µL) and the mixture was stirred for 3h 
in the same conditions. The mixture was concentrated and purified by flash column 
chromatography (10% ethyl acetate in dichloromethane). White solid (47% yield);             
mp: 45-47°C. 1H-NMR (300 MHz, CDCl3) 9 (bs, 1H, NH),                      
3.63 (d, J = 2.5 Hz, 2H, CH2CCH), 2.25 (t, J = 2.5 Hz, 1H, CH2CCH), 1.47 (s, 9H, Boc) 
ppm. 
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IV.5.2 Synthesis of tert-butyl 2-(5-bromo-2-chloropyrimidin-4-yl)-
2-(prop-2-yn-1-1yl)hydrazine carboxylate (36) 
 
To a solution of compound 35 (1.5 mmol, 254 mg) in dry ethanol 
(7.5 mL), was added 5-bromo-2,4-dichloro pyrimidine (1.8 mmol, 
410 mg, 230 µL) and diisopropylethylamine (3.75 mmol, 653 µL). 
The solution was refluxed for 5h. The solution was concentrated under reduced pressure 
and the crude was diluted with dichloromethane (30 mL) and washed with a saturated 
solution of ammonium chloride (2 x 30 mL). The combined organic extracts were dried 
over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (10% ethyl acetate in 
dichloromethane). Yellow solid (58% yield); mp: 140-142°C. 1H-NMR (300 MHz, CDCl3)   
Ar), 6.94 (bs, 1H, NH), 4.64 (bs, 2H, CH2CCH), 2.35 (t, J = 2.5 Hz, 1H, 
CH2CCH), 1.49 (bs, 9H, Boc) ppm. 13C-NMR (75 MHz, CDCl3 162.48 (CO), 160.95 
(Cq), 158.44 (Cq), 153.83 (CAR-H), 102.07 (Cq), 83.02 ((CH3)3C), 77.00 (CH2CCH), 74.28 
(CH2CCH), 41.51 (CH2CCH), 28.65 (OCCH3) ppm. 
 
IV.5.3 Synthesis of 1-(2-bromo-5-chlorophenyl)-1-(prop-2-yn-1-
yl)hydrazine (37) 
 
To a solution of compound 36 (0,85 mmol, 308.1 mg) in acetonitrile 
(6.54 mL, was added p-toluenesulfonic acid monohydrate (3.27 mmol, 
622 mg). The reaction was stirred overnight at room temperature. 
Then, the solvent was removed under reduced pressure and the crude 
was diluted with 1M solution of sodium carbonate (30 mL) and extracted with ethyl acetate 
(3 x 30 mL). The combined organic phases were dried over anhydrous sodium sulphate, 
filtered and concentrated under reduced pressure. White solid (100% yield); 1H-NMR (300 
MHz, CDCl3 = 8.32 (s, 1H, HAr), 4.59 (d, J = 2.4 Hz, 2H, CH2CCH), 4.30 (s, 2H, NH2), 
2.33 (t, J = 2.4 Hz, 1H, CH2CCH) ppm. 
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IV.5.4 Synthesis of tetraoxane ester (40) 
 
To a solution of ethyl-4-oxocyclohexane-1-carboxylate               
(5 mmol, 797 µL) in dry acetonitrile (5.5 mL) were added 
formic acid (3.7 mL) and hydrogen peroxide (1.9 mL, 50% 
aqueous solution) at 0ºC. After 1h of stirring at room temperature under nitrogen 
atmosphere the reaction mixture was diluted in dichloromethane (40 mL) and washed with 
distilled water (2 x 40 mL). The organic phase was dried with anhydrous sodium sulfate, 
filtered and concentrated under reduced pressure to give the gem-dihydroperoxide. The 
intermediate was dissolved in dry dichloromethane (5 mL) and added to a solution of 2-
adamantanone (7.5 mmol, 1.126 g) and rhenium (VII) oxide (0.068 mmol %, 33 mg) in dry 
dichloromethane (5 mL) at 0ºC. After stirring for 3h at room temperature under nitrogen 
atmosphere, the reaction mixture was filtrate in vacuum with a layer of silica. The filtrate 
was concentrated under reduced pressure and purified by flash column chromatography 
(5% ethyl acetate in hexane). White solid (53% yield); mp: 67-69°C. 1H-NMR (300 MHz, 
CDCl3  4.13 (q, J = 7.1 Hz, 2H, CH2CH3), 2.45-2.34 (m, 1H, CHCOOEt), 2.14-1.45 (m, 
22H, adam-H and cycloh-H), 1.24 (t, J = 7.1 Hz, 3H, CH2CH3) ppm. 13C-NMR (75 MHz, 
CDCl3 174.60 (CO), 110.50 (adamCOO), 107.19 (OOCcycloh), 60.40 (CH2CH3), 
41.68 (CHCOOEt), 39.26 (adam-CH2 and cyclo-CH2), 36.26 (adam-CH2 and cycloh-CH2), 
33.13 (adam-CH2 and cycloh-CH2), 27.05 (adam-CH), 14.21 (CH2CH3) ppm. 
 
IV.5.5 Synthesis of tetraoxane acid (41) 
 
 To a solution of compound 40 (0.14 mmol, 50 mg) in 
methanol (700 µL) was added 1M sodium hydroxide solution 
(700 µL) in distilled water (231 µL). The mixture was refluxed 
for 1h30, after which the solution was allowed to cool to room 
temperature and concentrated under reduced pressure. The crude was taken up in distilled 
water (30 mL) and extracted with diethyl ether (3 x 20 mL). The aqueous layer was acidified 
with concentrated hydrochloric acid to pH 1 and extracted with diethyl ether (3 x 20 mL). 
The combined organic phases were washed with brine solution (3 x 30 mL), dried over 
anhydrous sodium sulphate, filtered and concentrated under reduced pressure. White 
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solid (53% yield); mp: 151-153°C. 1H-NMR (300 MHz, CDCl3 -2.41 (m, 1H, 
CHCOOEt), 2.08-1.44 (m, 22H, adam-H and cycloh-H) ppm. 
 
IV.5.6 Synthesis of tetraoxane chloride acid (42) 
 
A mixture of compound 41 (0.67 mmol, 217.2 mg), thionyl 
chloride (59.28 mmol, 4.3 mL) and catalytic dimethylformamide 
was stirred for 2h in reflux. The solution was concentrated 
under reduced pressure. White solid (100% yield); 1H-NMR 
(300 MHz, CDCl3 92-2.79 (m, 1H, CHCOOEt), 2.17-1.46 (m, 22H, adam-H and 
cyclo-H) ppm. 
 
IV.5.7 Synthesis of tetraoxane-pyrimidine nitrile hybrid-Cl (43) 
A solution of compound 37 (0.95 mmol, 248.7 mg) 
in dry tetrahydrofuran (4.5 mL) was added to a 
solution of compound 42 in dry tetrahydrofuran (2 
mL). After stirring for 30 min at room temperature 
under nitrogen atmosphere diisopropylethylamine (2.85 mmol, 496 µL) was added. The 
mixture was refluxed overnight. The mixture was diluted with dichloromethane (30 mL) and 
washed with distilled water (30 mL) and the phases were separated. The aqueous phase 
was further extracted with dichloromethane (2 x 20 mL). The combined organic phases 
were dried over anhydrous sodium sulphate, filtered and concentrated under reduced 
pressure. The residue was purified by flash column chromatography (20% ethyl acetate in 
hexane). White solid (46 % yield); mp: 137-139°C. 1H-NMR (300 MHz, CDCl3  8.33 (s, 
1H, HAr), 7.79 (s, 1H, NH), 4.63 (bs, 2H, CH2CCH), 2.46-2.30 (m, 1H, CHCONH), 2.36 (t, 
J = 2.4 Hz, 1H, CH2CCH), 2.09-1.49 (m, 22H, adam-H and cycloh-H) ppm. 13C-NMR (75 
MHz, CDCl3 172.42 (CO), 161.92 (CAr-H), 160.79 (Cq), 158.20 (Cq), 110.70 
(adamCOO), 106.75 (OOCcycloh), 102.21 (Cq), 77.00 (CH2CCH), 74.38 (CH2CCH), 41.57 
(CHCOOEt), 40.72 (CH2CCH), 36.88 (adam-CH2 and cycloh-CH2), 33.12 (adam-CH2 and 
cycloh-CH2), 26.99 (adam-CH) ppm. 
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IV.5.8 Synthesis of tetraoxane-pyrimidine nitrile hybrid-CN (30) 
To a solution of compound 43 (0.377 mmol, 
214.3 mL) and 1,4-diazabicyclo[2,2,2]octane 
(0.377 mmol, 42.29 mg) in 
dimethylsulfoxide/water (9:1, 3.77 mL) was 
added potassium cyanide (0.415 mmol, 27 mg). After 4h30 of stirring at room temperature 
the reaction mixture was poured into ice water (40 mL) and extracted with ethyl acetate (3 
x 40 mL). The combined organic phases were washed with saturated sodium bicarbonate 
(2 x 30 mL), dried over anhydrous sodium sulphate, filtered and concentrated under 
reduced pressure. White solid (69% yield); mp: 143-145ºC. 1H-NMR (300 MHz, CDCl3
= 8.53 (s, 1H, HAr), 7.95 (s, 1H, NH), 4.62 (bs, 2H, CH2CCH), 2.48-2.32 (m, 1H, CHCONH), 
2.39 (t, J = 2.4 Hz, 1H, CH2CCH), 2.11-1.42 (m, 22H, adam-H and cycloh-H) ppm.             
13C-NMR (75 MHz, CDCl3 52 (CO), 160.93 (CAr-H), 160.18 (Cq), 141.55 (Cq), 
115.16 (CN), 110.72 (adamCOO), 107.20 (OOCcycloh), 106.69 (Cq), 76.57 (CH2CCH), 
74.77 (CH2CCH), 41.50 (cyclohCHCO), 40.96 (CH2CCH), 36.87 (adam-CH2 and        
cycloh-CH2), 33.11 (adam-CH2 and cyclo-CH2), 26.98 (adam-CH) ppm. 
 
IV.6 Synthesis of tetraoxane-pyrimidine nitrile probe
 
IV.6.1 Synthesis of N-(3-azidopropyl)-7-nitrobenzo[C][1,2,5] 
oxadiazol-4-amine (46) 
 
To a solution of 3-bromopropylamine hydrobromide (0.55 mmol, 120.4 
mg) in tetrahydrofuran/water (3:1, 1 mL) was added sodium azide (1.1 
mmol, 71.5 mg) and catalytic potassium iodide. The mixture was refluxed 
overnight and then cooled to room temperature. After was added 10N 
sodium hydroxide solution until pH 11. The mixture was diluted with brine solution (30 mL) 
and washed with dichloromethane (3 x 30 mL). The combined organic phases were dried 
with anhydrous sodium sulphate, filtered and partially concentrated under reduced 
pressure at low temperature. The resultant solution was diluted in methanol (3.5 mL) and 
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0.1N sodium hydrogen carbonate solution (10 mL). After was added 4-chloro-7-
nitrobenzoxadiazole (1.5 mmol) in methanol (5 mL) and the mixture was refluxed 3h. The 
solution was concentrated under reduced pressure and purified by flash column 
chromatography (50% ethyl acetate in hexane). Brown solid (33 % yield); mp: 59-61°C. 
1H-NMR (300 MHz, CDCl3)  = 8.47 (s, 1H, HAr), 6.64 (s, 1H, NH), 6.22 (d, J = 8.7 Hz, 1H, 
HAr), 3.66 (dd, J = 6.5, 12.8 Hz, 2H, NHCH2), 3.59 (t, J = 12.3 Hz, 2H, CH2N3), 2.07 (quint, 
J = 6.4 Hz, 2H, CH2CH2CH2) ppm. MS-ESI m/z: 264.1 [M + H]+. 
 
IV.6.2 Synthesis of tetraoxane-pyrimidine nitrile probe (32) 
 
To a stirring solution of compound 30 
(0.09 mmol, 50 mg) in dry 
dimethylformamide (900 µL) at room 
temperature under nitrogen 
atmosphere, cooper sulphate (92 µL, 
aqueous solution 25 mg/ 1 mL) and 
sodium ascorbate (92 µL, aqueous 
solution 40 mg/ 1 mL) were added dropwise. After 5 min, compound 46 was also added 
dropwise and the reaction was stirred at room temperature overnight. After 22h was added 
a solution of triethylamine (0.098 mmol, 13.7 µL) and the reaction was stirred for more 3h. 
The mixture was concentrated under reduced pressure, diluted with distilled water (15 mL) 
and extracted with ethyl acetate (4 x 15 mL). The combined organic phases were dried 
over anhydrous sodium sulphate, filtered and concentrated. The resulting residue was 
purified by preparative thin-layer chromatography (40 % ethyl acetate in hexane). Brown 
oil (32 % yield). 1H-NMR (300 MHz, CDCl3)  = 9.13 (s, 1H, CHtriazole), 8.43 (s, 1H, HAr-py r), 
8.35 (d, J = 8.7 Hz, 1H, HAr-NBD), 7.88 (s, 1H, cyclohCONH), 7.20 (m, 1H, CH2CH2CH2NH), 
6.16 (d, J = 8.7 Hz, 1H, HAr-NBD), 5.03 (s, 2H, NHNCH2), 4.70-4.55 (m, 2H, CH2CH2CH2), 
3.65-3.50 (m, 2H, CH2CH2CH2), 2.55-2.35 (m, 3H, CHCONH and CH2CH2CH2), 2.15-1.42 
(m, 22H, adam-H and cycloh-H) ppm. 13C-NMR (75 MHz, CDCl3
(CAr-py r), 159.84 (Cq), 144.22 (Cq), 143.83 (Cq), 141.95 (Cq), 141.21 (Cq), 136.70             
(CAr-NBD), 134.18 (CAr-triazole), 129.21, 128.24, 124.95, 123.57 (Cq), 115.43 (CN), 110.63 
(adamCOO), 107.06 (OOCcycloh), 106.78 (Cq), 99.22 (CAr-NBD), 47.72 (CH2CH2CH2), 
47.04 (NHNCH2), 41.01 (CHCONH), 40.80 (CH2CH2CH2), 36.82 (adam-CH2 and       
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cycloh-CH2), 33.07 (adam-CH2 and cycloh-CH2), 28.48 (CH2CH2CH2), 26.97 (adam-CH) 
ppm. MS-ESI m/z: 821.0 [M + H]+. 
 
IV.6 Synthesis of dioxane-pyrimidine nitrile hybrid
 
IV.6.1 Synthesis of adamantane-2-carbaldehyde (48) 
 
Method A: A solution of methoxymethyltriphenylphosphonium (5.83 mmol, 
1.9985 g) and potassium bis(trimethylsilyl)amide (0.5M in hexane, 11.66 
mL) in dry tetrahydrofuran (7.5 mL) was stirred for 15 min at 0ºC under 
nitrogen atmosphere. Then was added a solution of 2-adamantanone (4.16 
mmol, 625 mg) in dry tetrahydrofuran (2.5 mL) and the mixture was stirred for 2h in the 
same conditions. The solution was diluted with distilled water (30 mL) and extracted with 
diethyl ether (3 x 30 mL). The combined organic phases were dried with anhydrous sodium 
sulphate, filtered and concentrated under reduced pressure. The crude was dissolved in 
acetonitrile (25 mL) and hydrochloric acid (1M, 6,25 mL) was added and stirred for 21h at 
room temperature. The solution was diluted with brine soltution (30 mL) and extracted with 
diethyl ether (3 x 30 mL). The combined organic phases were dried over anhydrous sodium 
sulphate, filtered and concentrated under reduced pressure. White solid (42% yield);       
mp: 129-131°C. 1H-NMR (300 MHz, CDCl3 -2.36 (m, 3H), 
2.00-1.58 (m, 12H) ppm. 
Method B: A two-necked round-flask was charged with methoxymethyltriphenyl 
phosphonium (5 mmol, 1.717 g) and purged with nitrogen. Then was added dry diethyl 
ether (11.5 mL) and stirred at 0ºC for 10 min. n-buthyllithium was slowly added and the 
mixture changed from yellow to dark orange and stirred for 1h at 0ºC under nitrogen 
atmosphere. In another flask, 2-adamantanone (4.3 mmol, 646 mg) was dissolved in dry 
diethyl ether (7.12 mL) and the mixture was added dropwise to the previous flask. The 
mixture was allowed to stir for 16h30 at room temperature under nitrogen atmosphere. 
The solution was stirred vigorously while zinc chloride was added to complex with the 
suspended triphenylphosphine oxide. The ether layer was filtrated and concentrated under 
reduced pressure to yield the enol ether. The crude was dissolved in dry diethyl ether          
(8 mL) and were added perchloric acid (70%, 799 µL) and distilled water (444 µL). After 
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stirring for 1h in reflux, the mixture was poured into distilled water (50 mL). The organic 
layer was extracted with distilled water (2 x 50 mL), dried over anhydrous sodium sulphate, 
filtered and concentrated under reduced pressure. The desired product was not isolated. 
Method C: A solution of methoxymethyltriphenylphosphonium (5 mmol, 1.714 g) and 
sodium hydride (7.5 mmol, 179.9 mg) in dry tetrahydrofuran (6.43 mL) was stirred for 15 
min at 0ºC under nitrogen atmosphere. Then was added a solution of 2-adamantanone 
(3.57 mmol, 536.3 mg) in dry tetrahydrofuran (2.14 mL) and the mixture was stirred for 4h 
at room temperature. The solution was diluted with distilled water (30 mL) and washed 
with diethyl ether (3 x 30 mL). The combined organic phases were dried over anhydrous 
sodium sulphate, filtered and concentrated under reduced pressure. The crude was 
dissolved in acetonitrile (21,44 mL) and hydrochloric acid (1M, 5,36 mL) was added and 
stirred for 22h at room temperature. The solution was diluted with brine solution (30 mL) 
and extracted with diethyl ether (3 x 30 mL). The combined organic phases were dried 
over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The 
desired product was not isolated. 
 
IV.6.2 Synthesis of adamantane-2,2-diyldimethanol (49) 
 
To a solution of compound 48 (0.82 mmol, 134.8 mg) in tetrahydrofuran 
(161 µL) and methanol (241 µL) was added formaldehyde 37% (2.21 
mmol, 178 µL) at 0ºC. Sodium hydroxide (1.28 mmol, 204 µL, aqueous 
solution 25%) was carefully added and the solution was stirred at room temperature for 
19h. The mixture was poured into brine solution (20 mL) and extracted with 
tetrahydrofuran/ethyl acetate (1:1, 3 x 30 mL). The combined organic phases were dried 
with anhydrous sodium sulphate, filtered and concentrated under reduced pressure. Crude 
was purified by recrystallization from diethyl ether/hexane. White solid (49% yield);           
mp: 161-163 ºC. 1H-NMR (300 MHz, CDCl3)  = 3.94 (s, 4H, 2 x CH2OH), 2.72 (bs, 2H,     
2 x CH2OH), 2.06-1.95 (m, 4H, adam-H), 1.93-1.85 (m, 2H, adam-H), 1.80-1.68 (m, 4H, 
adam-H), 1.65-1.55 (m, 4H, adam-H) ppm. MS-ESI m/z: 197.1 [M + H]+. 
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IV.6.3 Synthesis of dioxane ester (50) 
 
Method A: A solution of compound 49 (0.11 mmol, 22.5 
mg), ethyl-4-oxocyclohexane-1-carboxylate (0.11 mmol, 
17.5 µL) and -toluenesulfonic acid (0.11 mmol, 18.9 mg) 
in dry toluene (1.5 mL) was heated at 125ºC in Dean-Stark conditions for 18h. The mixture 
was concentrated under reduced pressure. The desired product was not isolated. 
Method B: To a solution of compound 49 (0.73 mmol, 150 mg) in dry dichloromethane 
(4.45 mL) were added ethyl-4-oxocyclohexane-1-carboxylate (0.49 mmol, 77.7 µL), 
(EtO)3CH (0.49 mmol, 81.5 µL) and catalytic zirconium tetrachloride. The solution was 
stirred at room temperature for 75 min. The mixture was poured into 10% sodium 
hydroxide solution (20 mL) and extracted with dichloromethane (3 x 20 mL). The combined 
organic phases were washed with distilled water (3 x 40 mL), dried over anhydrous sodium 
sulphate, filtered and concentrated under reduced pressure. Crude was purified by flash 
column chromatography (20% ethyl acetate in hexane). Clear oil (86 % yield); 1H-NMR 
(300 MHz, CDCl3)  4.11 (q, J = 7.1 Hz, 2H, CH2CH3), 3.85 (s, 2H, CH2OH), 3.81 (s, 2H, 
CH2OH), 2.37-2.25 (m, 1H, CHCOOEt), 2.20-2.09 (m, 2H), 1.98-1.63 (m, 14H), 1.62-1.52 
(m, 4H), 1.47-1.34 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H, CH2CH3) ppm. 13C-NMR (75 MHz, 
CDCl3 175.34 (CO), 97.05 (adamC(CH2)2), 66.39 and 66.22 (adamC(CH2)2), 60.19 
(CH2CH3), 42.19 (dioxCHCONH), 38.88 (adam-CH2 and cycloh), 37.62 (adam-CH2 and 
cycloh), 32.42 (adam-CH2 and cycloh), 31.20 (adam-CH2 and cycloh), 30.91 (adam-CH), 
28.01 (adam-CH), 25.07 OOCcycloh), 14.23 (CH2CH3) ppm. 
 
IV.6.4 Synthesis of dioxane acid (51) 
 
To a solution of compound 50 (0.144 mmol, 50 mg) in 
methanol (720 µL) was added 10 M sodium hydroxide 
solution (72 µL) in distilled water (231 µL). The mixture was 
refluxed for 1h30, after which was allowed to cool to room temperature and concentrated 
under reduced pressure. The crude was taken up in distilled water (20 mL) and extracted 
with dichloromethane (3 x 20 mL). The aqueous layer was acidified with concentrated 
perchloric acid and extracted with dichloromethane (3 x 20 mL). The combined organic 
phases were washed with brine solution (2 x 40 mL), dried with anhydrous sodium sulphate 
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and concentrate under reduced pressure. Clear oil (74 %); 1H-NMR (300 MHz, CDCl3)       
 = 3.86 (s, 2H, CH2OH), 3.82 (s, 2H, CH2OH), 2.43-2.31 (m, 1H, CHCOOEt), 2.22-2.10 
(m, 2H), 1.98-1.37 (m, 20H) ppm 
 
IV.7 Synthesis of dioxane-pyrimidine nitrile hybrid (52)
 
A mixture of compound 51 (0.31 mmol, 98 mg), 
triethylamine (0.465 mmol, 64.7 µL) and 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate (0.31 mmol, 99 mg) in dry 
dichloromethane (9.12 mL) was stirred at 0ºC for 2h under nitrogen atmosphere. In another 
flask, compound 37 (0.31 mmol, 81.1 mg) was dissolved in dichloromethane (9.12 mL) 
and the mixture was added dropwise to the previous flask. The mixture was allowed to stir 
for 15 min at 0ºC under nitrogen atmosphere and then for 19h at room temperature. The 
mixture was poured into distilled water (25 mL) and extracted with ethyl acetate                      
(3 x 30 mL). The combined organic phases were washed with brine solution (3 x 40 mL), 
dried over anhydrous sodium sulphate and concentrate under reduced pressure. The 
desired product was not isolated.
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VI. Annexes  
 
 
VI.1 Tert-butyl 2-(prop-2-yn-1-yl)hydrazine carboxylate 
(35) 
 
 
Figure VI.1 - 1H-NMR spectrum (CDCl3) of compound 35. 
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VI.2 Tert-butyl 2-(5-bromo-2-chloropyrimidin-4-yl)-2-
(prop-2-yn-1-yl)hydrazine carboxylate (36) 
 
 
 
Figure VI.2 - 1H-NMR spectrum (CDCl3) of compound 36. 
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Figure VI.3 - COSY spectrum (CDCl3) of compound 36. 
 
 
Figure VI.4 - 13C-NMR spectrum (CDCl3) of compound 36. 
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Figure VI.5 - HMQC spectrum (CDCl3) of compound 36. 
 
 
Figure VI.6 - HMBC spectrum (CDCl3) of compound 36. 
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  Figure VI.7 - IR spectrum of compound 36. 
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VI.3 1-(2-bromo-5-chlorophenyl)-1-(prop-2-yn-1-
yl)hydrazine (37) 
 
 
 
Figure VI.8 - 1H-NMR spectrum (CDCl3) of compound 37. 
 
 
Figure VI.9  IR spectrum of compound 37. 
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VI.4 Tetraoxane ester (40) 
 
 
 
Figure VI.10 - 1H-NMR spectrum (CDCl3) of compound 40. 
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Figure VI.11  COSY spectrum (CDCl3) of compound 40. 
 
 
Figure VI.12 - 13C-NMR spectrum (CDCl3) of compound 40. 
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Figure VI.13  APT spectrum (CDCl3) of compound 40. 
 
 
Figure VI.14  HMQC spectrum (CDCl3) of compound 40. 
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Figure VI.15  HMBC spectrum (CDCl3) of compound 40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis and evaluation of chemical probes to study the biology of liver stage  malaria parasites 
VI.5 Tetraoxane acid (41) 
 
Figure VI.16 - 1H-NMR spectrum (CDCl3) of compound 41. 
 
Synthesis and evaluation of chemical probes to study the biology of liver stage  malaria parasites 
VI.6 Tetraoxane chloride acid (42) 
Figure VI.17 - 1H-NMR spectrum (CDCl3) of compound 42. 
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VI.7 Tetraoxane-pyrimidine nitrile hybrid-Cl (43) 
 
 
 
Figure VI.18 - 1H-NMR spectrum (CDCl3) of compound 43. 
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Figure VI.19  COSY spectrum (CDCl3) of compound 43. 
 
 
Figure VI.20 - 13C-NMR spectrum (CDCl3) of compound 43. 
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Figure VI.21  APT spectrum (CDCl3) of compound 43. 
 
 
Figure VI.22  HMQC spectrum (CDCl3) of compound 43. 
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Figure VI.23  HMBC spectrum (CDCl3) of compound 43. 
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VI.8 Tetraoxane-pyrimidine nitrile hybrid-CN (30) 
 
Figure VI.24 - 1H-NMR spectrum (CDCl3) of compound 30. 
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Figure VI.25  COSY spectrum (CDCl3) of compound 30. 
 
 
Figure VI.26 - 13C-NMR spectrum (CDCl3) of compound 30. 
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Figure VI.27  APT spectrum (CDCl3) of compound 30. 
 
 
Figure VI.28  HMQC spectrum (CDCl3) of compound 30. 
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Figure VI.29  HMBC spectrum (CDCl3) of compound 30. 
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VI.9 Chemical probe NBD (46) 
 
Figure VI.30 - 1H-NMR spectrum (CDCl3) of compound 46. 
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VI.10 Tetraoxane-pyrimidine nitrile probe (32) 
 
 
Figure VI.31 - 1H-NMR spectrum (CDCl3) of compound 32. 
 
 
Figure VI.32  COSY spectrum (CDCl3) of compound 32. 
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Figure VI.33 - 13C-NMR spectrum (CDCl3) of compound 32. 
 
 
Figure VI.34  APT spectrum (CDCl3) of compound 32. 
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Figure VI.35  HMQC spectrum (CDCl3) of compound 32. 
 
 
Figure VI.36  HMBC spectrum (CDCl3) of compound 32. 
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VI.11 Adamantane-2-carbaldehyde (48) 
 
Figure VI.37 - 1H-NMR spectrum (CDCl3) of compound 48. 
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VI.12 Adamantane-2,2-diyldimethanol (49) 
 
 
Figure VI.38 - 1H-NMR spectrum (CDCl3) of compound 49. 
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VI.13 Dioxane ester (50) 
 
 
 
Figure VI.39 - 1H-NMR spectrum (CDCl3) compound 50. 
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Figure VI.40  COSY spectrum (CDCl3) of compound 50. 
 
 
Figure VI.41 - 13C-NMR spectrum (CDCl3) of compound 50. 
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Figure VI.42  APT spectrum (CDCl3) of compound 50. 
 
 
Figure VI.43  HMQC spectrum (CDCl3) of compound 50. 
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Figure VI.44  HMBC spectrum (CDCl3) of compound 50. 
 
VI.13 Dioxane acid (51) 
 
 
Figure VI.45 - 1H-NMR spectrum (CDCl3) compound 51. 
